Drug resistance of cancer cells is crucially affected by expression levels of ABC-transporters
Dasatinib (DAS), a second generation of tyrosine kinase inhibitor (TKI), represents excellent choice for the treatment of chronic myeloid leukemia resistant to imatinib. Unfortunately, recent laboratory studies suggested that antiproliferative effect of DAS might be significantly reduced due to t...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Pensoft Publishers
2017-02-01
|
| Series: | BioDiscovery |
| Subjects: | |
| Online Access: | https://biodiscovery.pensoft.net/article/11211/download/pdf/ |